Clinical Trial Update: Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial comparing weekly versus every-3-weeks carboplatin plus paclitaxel in advanced epithelial ovarian cancer is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Cairo University | Conditions: Advanced Epithelial Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED